The US Food and Drug Administration has proposed new conflict-of-interest waiver guidelines that would publicly identify the companies or institutions at issue when an advisory panel member has a financial conflict1,2.
The proposal is aimed at boosting transparency behind the agency’s decision to grant waivers for conflicts of interest at advisory committee meetings...
Please login to read the full article.
